Questcor to Present At the Oppenheimer 19th Annual Healthcare Conference in New York: Financial News

Questcor to Present At the Oppenheimer 19th Annual Healthcare Conference in New York
Thursday October 23, 2008 6:00 am ET

UNION CITY, Calif., Oct. 23, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (NasdaqCM:QCOR - News) announced today that it will present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4, 2008 at the Waldorf-Astoria Hotel in New York City. Steve Cartt, Executive Vice President, Corporate Development and Dave Medeiros, Senior Vice President of Pharmaceutical Operations will discuss the Company's business strategy and financial performance at 4:00 p.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio webcast of Questcor's presentation may be accessed through the Company's website at http://www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at http://www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel (``Acthar'') and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (``MS''). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms (``IS''), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit http://www.questcor.com.